Ontology highlight
ABSTRACT: Pre-IBD is a transitional state between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), in which chronic high-fat diet intake and antibiotic exposure significantly increase intestinal inflammatory susceptibility. However, the underlying mechanisms and effective therapeutic strategies remain inadequately understood. Milk-derived extracellular vesicles (mEVs) have emerged as promising nanotherapeutic agents for alleviating gut disorders. In this study, we found that pre-IBD mice exhibited profound gut microbiota dysbiosis, and treatment with mEVs significantly alleviated intestinal inflammation by modulating MAPK-mediated M1/M2 macrophage polarization and restoring microbiota balance. Mechanistically, mEVs treatment led to a reduction in lysophosphatidylcholine (LPC) levels and an enrichment of Lactobacillus murinus (L. murinus), which exerted opposing effects on intestinal inflammation in both in vivo and in vitro models. Specifically, LPC exacerbated intestinal inflammation and structural alterations, whereas L. murinus treatment mitigated these pathological changes. Notably, both LPC and L. murinus interact with TLR2 but activate distinct downstream signaling pathways. LPC activates the TLR2/MAPK/NF-κB axis, promoting M1 polarization, whereas L. murinus binding to TLR2 induces M2 polarization. These findings demonstrate that mEVs reprogram the TLR2-mediated immune response by modulating the levels of L. murinus and LPC, thereby mitigating gut inflammation and contributing to the attenuation of pre-IBD pathology.
INSTRUMENT(S): Liquid Chromatography MS - negative - reverse phase, Liquid Chromatography MS - positive - reverse phase
PROVIDER: MTBLS14400 | MetaboLights | 2026-04-29
REPOSITORIES: MetaboLights
Items per page: 5 1 - 5 of 6 |